vs

Side-by-side financial comparison of First Savings Financial Group, Inc. (FSFG) and TScan Therapeutics, Inc. (TCRX). Click either name above to swap in a different company.

TScan Therapeutics, Inc. is the larger business by last-quarter revenue ($2.6M vs $1.5M, roughly 1.7× First Savings Financial Group, Inc.). First Savings Financial Group, Inc. runs the higher net margin — 350.2% vs -895.1%, a 1245.3% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs -0.7%). First Savings Financial Group, Inc. produced more free cash flow last quarter ($78.3M vs $-32.2M). Over the past eight quarters, TScan Therapeutics, Inc.'s revenue compounded faster (-9.7% CAGR vs -70.2%).

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

FSFG vs TCRX — Head-to-Head

Bigger by revenue
TCRX
TCRX
1.7× larger
TCRX
$2.6M
$1.5M
FSFG
Growing faster (revenue YoY)
TCRX
TCRX
+286.7% gap
TCRX
286.0%
-0.7%
FSFG
Higher net margin
FSFG
FSFG
1245.3% more per $
FSFG
350.2%
-895.1%
TCRX
More free cash flow
FSFG
FSFG
$110.4M more FCF
FSFG
$78.3M
$-32.2M
TCRX
Faster 2-yr revenue CAGR
TCRX
TCRX
Annualised
TCRX
-9.7%
-70.2%
FSFG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FSFG
FSFG
TCRX
TCRX
Revenue
$1.5M
$2.6M
Net Profit
$5.3M
$-23.0M
Gross Margin
Operating Margin
-929.4%
Net Margin
350.2%
-895.1%
Revenue YoY
-0.7%
286.0%
Net Profit YoY
43.5%
35.8%
EPS (diluted)
$0.76
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSFG
FSFG
TCRX
TCRX
Q4 25
$2.6M
Q3 25
$1.5M
$2.5M
Q2 25
$1.4M
$3.1M
Q1 25
$1.5M
$2.2M
Q4 24
$1.5M
Q3 24
$1.5M
$1.0M
Q2 24
$1.4M
Q1 24
$18.0M
Net Profit
FSFG
FSFG
TCRX
TCRX
Q4 25
$-23.0M
Q3 25
$5.3M
$-35.7M
Q2 25
$6.2M
$-37.0M
Q1 25
$5.5M
$-34.1M
Q4 24
$6.2M
Q3 24
$3.7M
$-29.9M
Q2 24
$4.1M
Q1 24
$4.9M
Operating Margin
FSFG
FSFG
TCRX
TCRX
Q4 25
-929.4%
Q3 25
-1475.6%
Q2 25
-1256.6%
Q1 25
-1669.7%
Q4 24
Q3 24
-3109.8%
Q2 24
Q1 24
32.1%
Net Margin
FSFG
FSFG
TCRX
TCRX
Q4 25
-895.1%
Q3 25
350.2%
-1422.1%
Q2 25
441.1%
-1201.3%
Q1 25
377.2%
-1571.9%
Q4 24
424.0%
Q3 24
242.4%
-2849.1%
Q2 24
295.8%
Q1 24
27.3%
EPS (diluted)
FSFG
FSFG
TCRX
TCRX
Q4 25
$-0.18
Q3 25
$0.76
$-0.28
Q2 25
$0.88
$-0.28
Q1 25
$0.79
$-0.26
Q4 24
$0.89
Q3 24
$0.53
$-0.25
Q2 24
$0.60
Q1 24
$0.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSFG
FSFG
TCRX
TCRX
Cash + ST InvestmentsLiquidity on hand
$31.9M
$152.4M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$193.5M
$123.1M
Total Assets
$2.4B
$228.8M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSFG
FSFG
TCRX
TCRX
Q4 25
$152.4M
Q3 25
$31.9M
$184.5M
Q2 25
$52.1M
$218.0M
Q1 25
$28.7M
$251.7M
Q4 24
$76.2M
Q3 24
$52.1M
$271.1M
Q2 24
$42.4M
Q1 24
$63.0M
Total Debt
FSFG
FSFG
TCRX
TCRX
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
Q1 25
$32.2M
Q4 24
Q3 24
$30.6M
Q2 24
Q1 24
Stockholders' Equity
FSFG
FSFG
TCRX
TCRX
Q4 25
$123.1M
Q3 25
$193.5M
$144.0M
Q2 25
$183.8M
$176.7M
Q1 25
$179.2M
$210.2M
Q4 24
$176.0M
Q3 24
$177.1M
$229.1M
Q2 24
$168.0M
Q1 24
$165.1M
Total Assets
FSFG
FSFG
TCRX
TCRX
Q4 25
$228.8M
Q3 25
$2.4B
$262.2M
Q2 25
$2.4B
$298.6M
Q1 25
$2.4B
$332.7M
Q4 24
$2.4B
Q3 24
$2.5B
$348.0M
Q2 24
$2.4B
Q1 24
$2.4B
Debt / Equity
FSFG
FSFG
TCRX
TCRX
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
Q1 25
0.15×
Q4 24
Q3 24
0.13×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSFG
FSFG
TCRX
TCRX
Operating Cash FlowLast quarter
$79.1M
$-32.0M
Free Cash FlowOCF − Capex
$78.3M
$-32.2M
FCF MarginFCF / Revenue
5199.5%
-1253.3%
Capex IntensityCapex / Revenue
58.4%
6.7%
Cash ConversionOCF / Net Profit
15.01×
TTM Free Cash FlowTrailing 4 quarters
$51.4M
$-139.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSFG
FSFG
TCRX
TCRX
Q4 25
$-32.0M
Q3 25
$79.1M
$-32.5M
Q2 25
$6.5M
$-33.3M
Q1 25
$-32.8M
$-37.6M
Q4 24
$177.0K
Q3 24
$91.2M
$-27.9M
Q2 24
$-655.0K
Q1 24
$7.7M
Free Cash Flow
FSFG
FSFG
TCRX
TCRX
Q4 25
$-32.2M
Q3 25
$78.3M
$-33.9M
Q2 25
$6.5M
$-34.5M
Q1 25
$-32.9M
$-39.1M
Q4 24
$-347.0K
Q3 24
$90.5M
$-29.3M
Q2 24
$-702.0K
Q1 24
$7.7M
FCF Margin
FSFG
FSFG
TCRX
TCRX
Q4 25
-1253.3%
Q3 25
5199.5%
-1349.6%
Q2 25
462.7%
-1123.1%
Q1 25
-2258.8%
-1801.8%
Q4 24
-23.6%
Q3 24
5974.9%
-2792.0%
Q2 24
-51.0%
Q1 24
42.6%
Capex Intensity
FSFG
FSFG
TCRX
TCRX
Q4 25
6.7%
Q3 25
58.4%
56.8%
Q2 25
0.5%
41.6%
Q1 25
8.7%
70.6%
Q4 24
35.7%
Q3 24
45.1%
130.6%
Q2 24
3.4%
Q1 24
0.0%
Cash Conversion
FSFG
FSFG
TCRX
TCRX
Q4 25
Q3 25
15.01×
Q2 25
1.05×
Q1 25
-5.97×
Q4 24
0.03×
Q3 24
24.84×
Q2 24
-0.16×
Q1 24
1.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons